Brazil is more than a market. It is a clinical development opportunity.
For biotech companies developing therapies for rare and ultra-rare diseases, Brazil can represent far more than international expansion. With a single-market population of more than 200 million people, advanced academic hospitals, experienced investigators, large public-health programs, deep patient cohorts and significant unmet medical need, Brazil offers a strategic pathway for clinical validation, patient identification, real-world evidence generation, regulatory development and long-term access.
Brazil requires the right clinical relationships, regulatory understanding, institutional credibility, data intelligence and local execution strategy. Pharma²⁸ provides the bridge between biotech innovation and Brazil's clinical, regulatory, research and patient-access ecosystem.
Brazil combines scale, medical expertise, patient diversity and unmet need in a way that is highly relevant for rare and ultra-rare disease programs. For selected therapies, Brazil may offer:
Access to a large and diverse patient population
More than 200 million people in a single market.
Deep patient cohorts
Across rare, underdiagnosed and complex conditions.
High-volume expert centers and academic hospitals
With international-caliber investigators.
Experienced investigators and physician-scientists
Publishing to international standards.
Real-world clinical experience
And underused institutional knowledge.
Public-health and specialty-care infrastructure
At national scale.
Opportunities for clinical collaboration
And evidence generation.
A single regulatory pathway
Into one of the world's largest healthcare markets.
Long-term access potential
Through both private and public healthcare systems.
Brazil's strengths are powerful, but fragmented.
Biotech companies often face several barriers when trying to evaluate or enter the Brazilian market:
Identifying the right physicians and centers of excellence
With relevant disease-area expertise.
Understanding where relevant patients may be concentrated
Across institutions and regions.
Navigating regulatory and institutional pathways
With realistic timelines.
Evaluating early access, compassionate use or clinical study opportunities
Aligned with medical need.
Connecting academic, clinical, public-sector and private-sector stakeholders
Under one coherent plan.
Interpreting fragmented clinical and real-world data
Turning noise into decisions.
Building credibility with local medical leaders and institutions
Trust is earned, not assumed.
Aligning market access strategy with clinical and regulatory realities
Grounded in local context.
Without the right partner, the opportunity can appear difficult to access, slow to activate or too uncertain to prioritize. Pharma²⁸ was created to solve that gap.
Pharma²⁸ connects U.S. biotech innovation with Brazil's clinical, regulatory, institutional, data and patient-access ecosystem.
Based in Kendall Square, Cambridge, at the center of the Boston biotech ecosystem, Pharma²⁸ works with biotech companies to evaluate whether Brazil should be part of their international strategy — and, when the opportunity is aligned, to help structure a responsible path forward.
Our approach combines:
Clinical and medical feasibility assessment
Grounded in disease-area credibility.
Disease-area and patient-population mapping
Where relevant patients may be identified.
Physician and center-of-excellence engagement
Trusted specialist relationships.
Regulatory pathway support
ANVISA, access and evidence strategy.
Academic and institutional partnership development
Structured collaboration with credible institutions.
Real-world evidence and data-generation strategy
Fragmented information turned into decisions.
Early access and patient-access planning
Responsible pathways for high-need therapies.
AI-enabled rare disease intelligence
Human judgment supported by structured data.
Strategic coordination
Between U.S. biotech teams and Brazilian stakeholders.
Patient volume alone is not enough.
For rare and ultra-rare diseases, the real value comes from understanding where relevant patients may be found, which physicians and institutions have the right expertise, what clinical and laboratory patterns may matter, what real-world evidence already exists and how fragmented information can be translated into development decisions.
Pharma²⁸ integrates medical expertise, curated disease evidence, market intelligence, physician networks and AI-enabled data infrastructure to support patient identification, cohort mapping, evidence generation and strategic decision-making.
This intelligence layer helps biotech companies evaluate Brazil not only as a destination for market entry, but as a potential clinical development advantage.
Eight steps, from disease landscape to long-term adoption.
A successful Brazil strategy is not only about registration or distribution. For rare disease therapies, market entry often depends on a broader sequence of clinical and strategic steps:
- 01
Understanding the disease landscape
Epidemiology, natural history and existing clinical experience.
- 02
Identifying relevant physicians and centers
Specialists and institutions with real experience.
- 03
Mapping potential patient cohorts
Phenotypic and geographic mapping of relevant populations.
- 04
Evaluating regulatory and access pathways
ANVISA, CONITEC, RENAME, expanded and compassionate access.
- 05
Generating local evidence and clinical credibility
Real-world data with Brazilian medical trust.
- 06
Engaging institutions and stakeholders
Academic, public and private alignment.
- 07
Structuring early access or development opportunities
Clinical collaboration and evidence generation.
- 08
Building a long-term path toward adoption
Reimbursement, distribution and continuity of care.
Pharma²⁸ supports this process from strategic assessment through activation, helping biotech companies move from interest to execution with stronger clinical, regulatory and data alignment.
Pharma²⁸ works with biotech companies, clinical development teams, medical affairs leaders, business development executives, investors, research institutions, physicians and strategic partners exploring Brazil as part of an international rare disease strategy.
We are especially focused on therapies where scientific innovation, unmet medical need, patient identification and international access opportunities intersect.
If your company is developing a therapy for a rare or ultra-rare disease, Brazil may represent a meaningful opportunity for clinical collaboration, patient identification, real-world evidence, regulatory development and long-term patient access.
Pharma²⁸ can help you evaluate the opportunity, identify the right pathway and connect with the clinical, institutional, regulatory and data assets needed to move forward responsibly.
Let's connect.
If you are exploring international opportunities for a rare disease therapy, clinical program, data initiative or strategic partnership, we would welcome the opportunity to connect.